MCID: LYM118
MIFTS: 67

Lymphoma

Categories: Blood diseases, Cancer diseases, Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Lymphoma

MalaCards integrated aliases for Lymphoma:

Name: Lymphoma 12 74 58 29 54 6 42 44 15 17 71
Lymphoid Neoplasm 71
Lymphoid Cancers 71
Lymphoid Cancer 12
Lymphomas 15

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0060058
MeSH 44 D008223
NCIt 50 C3208 C7065
SNOMED-CT 67 118600007 414628006
ICD10 32 C85.9
MESH via Orphanet 45 D008223
UMLS via Orphanet 72 C0024299
Orphanet 58 ORPHA223735
UMLS 71 C0024299 C0598798 C0746336

Summaries for Lymphoma

MedlinePlus : 42 Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss Fever Soaking night sweats Coughing, trouble breathing or chest pain Weakness and tiredness that don't go away Pain, swelling or a feeling of fullness in the abdomen Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute

MalaCards based summary : Lymphoma, also known as lymphoid neoplasm, is related to lymphoma, non-hodgkin, familial and diffuse large b-cell lymphoma. An important gene associated with Lymphoma is PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), and among its related pathways/superpathways are Cytokine Signaling in Immune system and IL-2 Pathway. The drugs Entecavir and Ferrous succinate have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are cellular and endocrine/exocrine gland

Disease Ontology : 12 A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs.

Wikipedia : 74 Lymphoma is a group of blood malignancies that develop from lymphocytes (a type of white blood cell).... more...

Related Diseases for Lymphoma

Diseases in the Lymphoma family:

Adult Lymphoma Eye Lymphoma

Diseases related to Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2937)
# Related Disease Score Top Affiliating Genes
1 lymphoma, non-hodgkin, familial 33.9 TP53 TCL1A MYD88 MYC MALT1 EZH2
2 diffuse large b-cell lymphoma 33.9 TP53 MYD88 MYC MALT1 EZH2 CCND1
3 lymphoma, hodgkin, classic 33.8 PVT1 BCL6 BCL2 ALK
4 lymphoma, mucosa-associated lymphoid type 33.8 TP53 MYD88 MYC MALT1 CXCR5 CCND1
5 follicular lymphoma 33.8 MYC EZH2 CXCR5 CCND1 BCL6 BCL2
6 primary central nervous system lymphoma 33.6 MYD88 CXCR5 BCL6 BCL2
7 burkitt lymphoma 33.5 TP53 TCL1A PVT1 PMS2 MYC CXCR5
8 peripheral t-cell lymphoma 33.5 TP53 TCL1A CCND1 BCL6 ALK
9 marginal zone b-cell lymphoma 33.5 MYD88 MALT1 CCND1 BCL6 BCL2 BCL10
10 b-cell lymphoma 33.4 TP53 TCL1A PVT1 MYD88 MYC MALT1
11 gastric lymphoma 33.4 TP53 CXCR5 BCL6 BCL2 BCL10
12 intraocular lymphoma 33.4 CXCR5 BCL6 BCL2
13 central nervous system lymphoma 33.4 TP53 MYD88 MYC MALT1 CXCR5 BCL6
14 lymphoma aids related 33.3 TCL1A MYC BCL6
15 lymphoblastic lymphoma 33.2 TP53 MYC BCL6
16 mature t-cell and nk-cell lymphoma 33.2 TP53 MYC BCL6 ALK
17 reticulosarcoma 33.2 MYC BCL6 BCL2 ALK
18 sezary's disease 33.2 TP53 MYC BCL6 BCL10 ALK
19 leukemia, acute lymphoblastic 33.2 TP53 TCL1A PTPN11 MYC CXCR5 BCL6
20 splenic marginal zone lymphoma 33.2 MALT1 EZH2 BCL6
21 primary mediastinal b-cell lymphoma 33.1 TCL1A BCL6 BCL2
22 follicular lymphoma 1 33.1 BCL6 BCL2
23 plasmablastic lymphoma 33.0 MYC BCL6
24 bone lymphoma 32.9 BCL6 ALK
25 alk-negative anaplastic large cell lymphoma 32.9 MYC BCL2 ALK
26 mantle cell lymphoma 32.9 TP53 TCL1A MYC MALT1 GAS5 EZH2
27 lung lymphoma 32.8 MALT1 BCL6
28 b-cell non-hodgkin lymphoma 32.8 BCL7A BCL6
29 intravascular large b-cell lymphoma 32.8 MYD88 BCL6 BCL2
30 t-cell acute lymphoblastic leukemia 32.8 TP53 MYC EZH2 BCL10
31 breast lymphoma 32.8 BCL6 ALK
32 nodular lymphocyte predominant hodgkin lymphoma 32.8 CCND1 BCL6
33 gastrointestinal lymphoma 32.8 MALT1 CCND1 BCL6
34 orbit lymphoma 32.8 MALT1 BCL10
35 b-lymphoblastic leukemia/lymphoma 32.7 PTPN11 MYC CXCR5 ALK
36 cll/sll 32.7 TP53 EZH2 CCND1 BCL6
37 pediatric lymphoma 32.7 TCL1A MYC BCL6 ALK
38 gallbladder lymphoma 32.7 MALT1 CCND1 BCL6
39 nodal marginal zone b-cell lymphoma 32.7 MALT1 BCL6 BCL2
40 precursor t-cell acute lymphoblastic leukemia 32.7 TCL6 TCL1A MYC
41 eye lymphoma 32.7 CXCR5 BCL6
42 paranasal sinus lymphoma 32.7 MYC BCL6
43 adult lymphoma 32.7 MYC BCL6 ALK
44 retina lymphoma 32.6 CXCR5 BCL10
45 primary cutaneous marginal zone b-cell lymphoma 32.6 MALT1 BCL10
46 leukemia, chronic lymphocytic 32.6 TP53 TCL1A PTPN11 MYD88 MYC DLEU2
47 heart lymphoma 32.6 BCL6 ALK
48 primary cutaneous diffuse large b-cell lymphoma, leg type 32.5 MYD88 MYC
49 appendix lymphoma 32.5 MYC BCL6
50 t-cell lymphoblastic leukemia/lymphoma 32.5 TCL1A MYC GAS5 CCND1 BCL2

Graphical network of the top 20 diseases related to Lymphoma:



Diseases related to Lymphoma

Symptoms & Phenotypes for Lymphoma

MGI Mouse Phenotypes related to Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 BCL10 BCL2 BCL6 CCND1 CXCR5 EZH2
2 endocrine/exocrine gland MP:0005379 10.11 ALK BCL10 BCL2 BCL6 CCND1 EZH2
3 hematopoietic system MP:0005397 10.1 BCL10 BCL2 BCL6 CCND1 CXCR5 EZH2
4 immune system MP:0005387 10.03 BCL10 BCL2 BCL6 CCND1 CXCR5 EZH2
5 integument MP:0010771 9.81 ALK BCL2 BCL6 CCND1 EZH2 MALT1
6 neoplasm MP:0002006 9.61 ALK BCL2 CCND1 EZH2 MYC MYD88
7 reproductive system MP:0005389 9.32 ALK BCL2 BCL6 CCND1 MYC MYD88

Drugs & Therapeutics for Lymphoma

Drugs for Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 803)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
2
Ferrous succinate Approved Phase 4 10030-90-7
3
Nicotine Approved Phase 4 54-11-5 942 89594
4
Teniposide Approved Phase 4 29767-20-2 34698
5
Palonosetron Approved, Investigational Phase 4 135729-56-5, 119904-90-4 148211
6
Nitric Oxide Approved Phase 4 10102-43-9 145068
7
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
8
Infliximab Approved Phase 4 170277-31-3
9
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
10
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
11
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
12
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
13
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
14
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
15
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
16
Prilocaine Approved Phase 4 721-50-6 4906
17
tannic acid Approved Phase 4 1401-55-4
18
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
19
Epirubicin Approved Phase 4 56420-45-2 41867
20
Blinatumomab Approved, Investigational Phase 4 853426-35-4
21
Ledipasvir Approved Phase 4 1256388-51-8 67505836
22
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
23
Zidovudine Approved Phase 4 30516-87-1 35370
24
Methoxsalen Approved Phase 4 298-81-7 4114
25
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
26
Ribavirin Approved Phase 4 36791-04-5 37542
27
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
28
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
29
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
30
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
31
Fotemustine Investigational Phase 4 92118-27-9
32 Clorazepate Dipotassium Phase 4
33
Ethylene Phase 4 74-85-1 6325
34 Analgesics, Non-Narcotic Phase 4
35 Serotonin 5-HT3 Receptor Antagonists Phase 4
36 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
37 Ionophores Phase 4
38 Calcium Ionophores Phase 4
39 Anesthetics Phase 4
40 Anesthetics, Local Phase 4
41 Anesthetics, General Phase 4
42 Ketorolac Tromethamine Phase 4
43 Anesthetics, Dissociative Phase 4
44 Excitatory Amino Acid Antagonists Phase 4
45 Iron Supplement Phase 4
46 Anesthetics, Inhalation Phase 4
47 Vitamin D2 Phase 4
48 Ergocalciferols Phase 4
49 Hydroxycholecalciferols Phase 4
50 Sodium Channel Blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 6653)
# Name Status NCT ID Phase Drugs
1 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
2 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
3 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Unknown status NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
4 Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas Unknown status NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
5 Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL) Unknown status NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
6 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
7 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Unknown status NCT03579082 Phase 4 Decitabine
8 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Unknown status NCT03558412 Phase 4 Decitabine
9 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
10 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Unknown status NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
11 A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Unknown status NCT03150602 Phase 4 Pralatrexate
12 A Randomized Controlled Clinical Trial of Apatinib Combined With CHOP Regimen in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Unknown status NCT03631862 Phase 4 Apatinib;CHOP Regimen
13 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
14 EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial Unknown status NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
15 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE (MTX,DEX,IFO,L-ASP,Etoposide,Mesna)
16 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501136 Phase 4
17 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
18 The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma. Unknown status NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
19 A Single Center Randomized Controlled Trial of the Efficacy and Safety of PEG-rhG-CSF After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
20 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Unknown status NCT02929615 Phase 4
21 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
22 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
23 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
24 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
25 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
26 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
27 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
28 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
29 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
30 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
31 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
32 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
33 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
34 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
35 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
36 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
37 AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4 Aprepitant;Palonosetron;Granisetron
38 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
39 Assisted Oocyte Activation (AOA) in Recurrent Fertilization Failure Completed NCT04744753 Phase 4 Calcium Ionophore A23187
40 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
41 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
42 UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
43 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
44 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
45 Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
46 A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide ) Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
47 Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma Completed NCT01007448 Phase 4 Bexarotene
48 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
49 Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study Completed NCT01569724 Phase 4
50 Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine

Search NIH Clinical Center for Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


ASPARAGINASE
Cytarabine
Cytarabine liposome
irinotecan
Irinotecan hydrochloride
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa

Cochrane evidence based reviews: lymphoma

Genetic Tests for Lymphoma

Genetic tests related to Lymphoma:

# Genetic test Affiliating Genes
1 Lymphoma 29

Anatomical Context for Lymphoma

MalaCards organs/tissues related to Lymphoma:

40
T Cells, Bone, Bone Marrow, Breast, Myeloid, Skin, B Cells

Publications for Lymphoma

Articles related to Lymphoma:

(show top 50) (show all 57530)
# Title Authors PMID Year
1
Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic : Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance. 61 42
33125504 2020
2
Liquid biopsy in lymphoma: Molecular methods and clinical applications. 42 61
33049623 2020
3
Unusual disseminated Talaromyces marneffei infection mimicking lymphoma in a non-immunosuppressed patient in East China: a case report and review of the literature. 61 42
33115429 2020
4
Common misdiagnoses in lymphomas and avoidance strategies. 54 61
20227918 2010
5
Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. 54 61
20484818 2010
6
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. 54 61
20299510 2010
7
Oncogenic activation of NF-kappaB. 61 54
20516126 2010
8
Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. 61 54
20207982 2010
9
C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. 61 54
20015877 2010
10
Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice. 61 54
20124219 2010
11
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. 54 61
20197552 2010
12
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. 54 61
20190192 2010
13
Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis. 61 54
20179179 2010
14
Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. 61 54
20185581 2010
15
microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. 61 54
20086245 2010
16
Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. 61 54
20406193 2010
17
Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. 54 61
20062012 2010
18
An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma. 61 54
20490333 2010
19
C-C chemokine receptor 1 expression in human hematolymphoid neoplasia. 61 54
20154287 2010
20
Determining the expression rate of the IgM and IgA in B cell lymphomas by immunohistochemistry. 61 54
20437688 2010
21
Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. 54 61
19196381 2010
22
CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. 54 61
20004001 2010
23
PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis. 61 54
20087161 2010
24
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. 54 61
20054396 2010
25
A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy. 61 54
19965652 2010
26
B-cell CLL/lymphoma 10 (BCL10) is required for NF-kappaB production by both canonical and noncanonical pathways and for NF-kappaB-inducing kinase (NIK) phosphorylation. 54 61
19897484 2010
27
BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. 61 54
20510734 2010
28
Lymphoma cells contribute to the augmentation of plasma sL-selectins in the serum of lymphoma-bearing mice. 54 61
20001233 2010
29
Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. 61 54
20023257 2010
30
Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas. 54 61
19716163 2009
31
Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. 61 54
19963099 2009
32
Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. 54 61
19625084 2009
33
Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling. 54 61
19815557 2009
34
Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth. 54 61
20043832 2009
35
Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome. 54 61
19816150 2009
36
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. 61 54
19966776 2009
37
Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? 61 54
19358142 2009
38
To the genesis of Burkitt lymphoma: regulation of apoptosis by EBNA-1 and SAP may determine the fate of Ig-myc translocation carrying B lymphocytes. 61 54
19874894 2009
39
Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR. 54 61
19608671 2009
40
The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. 61 54
19551857 2009
41
Targeted deletion of p73 in mice reveals its role in T cell development and lymphomagenesis. 61 54
19907659 2009
42
Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-cells. 54 61
19725825 2009
43
AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. 54 61
19941823 2009
44
Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. 54 61
19880779 2009
45
[Immunohistochemical study using T-cell lymphoma antibody 1 and CD44 in diagnosis of Burkitt's lymphoma]. 54 61
20079013 2009
46
SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. 61 54
19880778 2009
47
Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma. 54 61
19633642 2009
48
CD44 expression during tumor progression of follicular lymphoma. 54 61
19787231 2009
49
Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma. 54 61
19696203 2009
50
Identification of MNDA as a new marker for nodal marginal zone lymphoma. 54 61
19474799 2009

Variations for Lymphoma

ClinVar genetic disease variations for Lymphoma:

6 (show all 14)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PMS2 NM_000535.7(PMS2):c.736_741delinsTGTGTGTGAAG (p.Pro246_Pro247delinsCysValTer) Indel Pathogenic 91366 rs267608150 7:6037019-6037024 7:5997388-5997393
2 PTPN11 NM_002834.5(PTPN11):c.188A>G (p.Tyr63Cys) SNV Pathogenic 13333 rs121918459 12:112888172-112888172 12:112450368-112450368
3 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
4 KMT2D NM_003482.3(KMT2D):c.10622_10623CT[1] (p.Leu3542fs) Microsatellite Likely pathogenic 638279 rs1592123162 12:49427965-49427966 12:49034182-49034183
5 KMT2D NM_003482.3(KMT2D):c.11897_11911del (p.Phe3966_Gln3971delinsTer) Deletion Likely pathogenic 638280 rs1592119138 12:49426577-49426591 12:49032794-49032808
6 SETBP1 NM_015559.3(SETBP1):c.1703G>T (p.Ser568Ile) SNV Likely pathogenic 638281 rs1599367044 18:42531008-42531008 18:44951043-44951043
7 EZH2 NM_004456.4(EZH2):c.1936T>A (p.Tyr646Asn) SNV Likely pathogenic 376217 rs267601395 7:148508728-148508728 7:148811636-148811636
8 EZH2 NM_004456.4(EZH2):c.1937A>C (p.Tyr646Ser) SNV Likely pathogenic 376218 rs267601394 7:148508727-148508727 7:148811635-148811635
9 MYD88 NM_002468.5(MYD88):c.755T>C (p.Leu252Pro) SNV Likely pathogenic 37055 rs387907272 3:38182641-38182641 3:38141150-38141150
10 EZH2 NM_004456.5(EZH2):c.1936T>C (p.Tyr646His) SNV Likely pathogenic 76769 rs267601395 7:148508728-148508728 7:148811636-148811636
11 EZH2 NM_004456.5(EZH2):c.1937A>T (p.Tyr646Phe) SNV Likely pathogenic 76768 rs267601394 7:148508727-148508727 7:148811635-148811635
12 EZH2 NM_004456.4(EZH2):c.2045C>G (p.Ala682Gly) SNV Likely pathogenic 376219 rs1057519833 7:148506467-148506467 7:148809375-148809375
13 IDH1 NM_001282386.1(IDH1):c.784G>A (p.Glu262Lys) SNV Uncertain significance 638277 rs1574404027 2:209106784-209106784 2:208242060-208242060
14 NSD2 NM_001042424.3(NSD2):c.3295G>A (p.Glu1099Lys) SNV Uncertain significance 638278 rs772470710 4:1962801-1962801 4:1961074-1961074

Copy number variations for Lymphoma from CNVD:

7 (show all 24)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 22797 1 168900 170100 Copy number Lymphoma
2 23565 1 171600 171900 Copy number Lymphoma
3 23675 1 172800 176700 Copy number Lymphoma
4 25326 1 187500 188100 Copy number Lymphoma
5 82146 14 105300 105900 Copy number Lymphoma
6 83536 14 21300 22200 Copy number Lymphoma
7 149232 2 88800 89400 Copy number Lymphoma
8 159014 21 39019555 39028514 Amplification KCNJ6 Lymphoma
9 159212 21 41403021 41411848 Amplification DSCAM Lymphoma
10 159621 21 43701285 43716936 Amplification ABCG1 Lymphoma
11 159656 21 43999157 44011961 Amplification SLC37A1 Lymphoma
12 159668 21 44081762 44094899 Amplification PDE9A Lymphoma
13 159699 21 44433424 44441413 Amplification PKNOX1 Lymphoma
14 159719 21 44574984 44589646 Amplification Lymphoma
15 159916 21 45919335 45928378 Amplification TSPEAR Lymphoma
16 159943 21 46246130 46270192 Amplification PTTG1IP Lymphoma
17 162160 22 21300 21600 Copy number Lymphoma
18 205715 6 13200 17100 Copy number Lymphoma
19 208659 6 1800 4200 Copy number Lymphoma
20 208796 6 19800 23100 Copy number Lymphoma
21 213994 6 5400 6300 Copy number Lymphoma
22 220996 7 141900 142200 Copy number Lymphoma
23 224818 7 38100 38700 Copy number Lymphoma
24 233910 8 128816946 128822855 Amplification MYC Lymphoma

Expression for Lymphoma

Search GEO for disease gene expression data for Lymphoma.

Pathways for Lymphoma

Pathways related to Lymphoma according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.29 TP53 PTPN11 MYD88 MYC CCND1 BCL6
2
Show member pathways
13.14 TP53 MYD88 MYC MALT1 CCND1 BCL2
3
Show member pathways
12.81 TP53 PTPN11 MYC CCND1 BCL2
4 12.78 TP53 MYC CCND1 BCL2 ALK
5
Show member pathways
12.76 TP53 MYD88 MYC CCND1 BCL2
6
Show member pathways
12.52 TP53 PTPN11 MYC CCND1 BCL2
7
Show member pathways
12.46 PTPN11 MYD88 MALT1 BCL10 ALK
8
Show member pathways
12.43 PTPN11 MYC CCND1 BCL2
9 12.42 MYD88 MALT1 CXCR5 BCL6 BCL10
10
Show member pathways
12.39 PTPN11 MALT1 BCL6 BCL10
11 12.38 TP53 MYC EZH2 CCND1 BCL2
12
Show member pathways
12.35 PTPN11 MYC CCND1 BCL2
13
Show member pathways
12.33 TP53 PTPN11 MYC CCND1
14
Show member pathways
12.3 TP53 MYC CCND1 BCL2
15 12.23 TP53 PTPN11 MYC CCND1
16
Show member pathways
12.22 PTPN11 MYC MALT1 BCL6 BCL10
17 12.19 TP53 MYD88 MALT1 BCL2 BCL10
18 12.15 MYD88 MALT1 BCL2 BCL10
19
Show member pathways
12.13 PTPN11 MYD88 MALT1 BCL10
20 12.04 TP53 MYC CCND1 BCL2
21 11.92 PTPN11 MYC MALT1 BCL2 BCL10
22 11.9 TP53 PMS2 BCL6 BCL2
23
Show member pathways
11.84 PTPN11 MYC BCL2
24 11.78 TP53 MYC CCND1
25 11.77 MYD88 MALT1 BCL2 BCL10
26 11.71 MYC CCND1 BCL2
27 11.67 TP53 MYC CCND1
28 11.63 TP53 MYC CCND1 BCL2
29
Show member pathways
11.62 PTPN11 MYC BCL2
30 11.57 MYC CCND1 BCL2
31 11.47 TP53 CCND1 BCL2
32 11.45 TP53 MYC CCND1
33 11.41 TP53 MYC CCND1 BCL6 BCL2
34 11.4 TP53 MYC BCL2
35 11.36 TP53 MYC CCND1
36 11.16 TP53 PTPN11 MYC CCND1
37 11.08 TP53 MYC CCND1 BCL6 BCL2
38
Show member pathways
10.84 TP53 MYC BCL2

GO Terms for Lymphoma

Cellular components related to Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.28 TP53 TCL1A PTPN11 MYD88 MYC MALT1
2 CBM complex GO:0032449 9.16 MALT1 BCL10
3 polkadots GO:0002096 8.96 MALT1 BCL10

Biological processes related to Lymphoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10 TCL1A MYC EZH2 CCND1 BCL2
2 cellular response to DNA damage stimulus GO:0006974 9.85 TP53 PMS2 MYC CCND1 BCL6 BCL2
3 response to drug GO:0042493 9.83 TP53 PMS2 MYC CCND1 BCL2
4 positive regulation of interleukin-6 production GO:0032755 9.76 PTPN11 MYD88 BCL10
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.76 MYD88 MALT1 BCL10 ALK
6 cellular response to mechanical stimulus GO:0071260 9.74 PTPN11 MYD88 BCL10
7 B cell differentiation GO:0030183 9.73 EZH2 BCL6 BCL2
8 negative regulation of apoptotic process GO:0043066 9.7 TP53 TCL1A MYD88 MYC MALT1 BCL6
9 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.67 MYC MALT1 BCL10
10 regulation of cell proliferation GO:0042127 9.65 TP53 MYD88 EZH2 BCL6 ALK
11 immunoglobulin mediated immune response GO:0016064 9.61 MYD88 BCL10
12 positive regulation of histone deacetylation GO:0031065 9.59 TP53 BCL6
13 organ growth GO:0035265 9.58 PTPN11 BCL2
14 lipopolysaccharide-mediated signaling pathway GO:0031663 9.58 MYD88 MALT1 BCL10
15 mitotic G1 DNA damage checkpoint GO:0031571 9.55 TP53 CCND1
16 regulation of T cell receptor signaling pathway GO:0050856 9.54 MALT1 BCL10
17 response to fungus GO:0009620 9.52 MALT1 BCL10
18 T cell lineage commitment GO:0002360 9.51 TP53 BCL2
19 response to gamma radiation GO:0010332 9.5 TP53 MYC BCL2
20 B cell lineage commitment GO:0002326 9.48 TP53 BCL2
21 regulation of apoptotic process GO:0042981 9.43 TP53 MALT1 BCL6 BCL2 BCL10 ALK
22 cytokine-mediated signaling pathway GO:0019221 9.17 TP53 PTPN11 MYD88 MYC CCND1 BCL6

Molecular functions related to Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.92 TP53 TCL1A MYD88 MALT1 BCL6 BCL2
2 protein kinase binding GO:0019901 9.77 TP53 TCL1A PTPN11 CCND1 BCL10
3 transcription factor binding GO:0008134 9.55 TP53 MYC CCND1 BCL2 BCL10
4 kinase activator activity GO:0019209 9.26 MALT1 BCL10
5 protease binding GO:0002020 9.26 TP53 MALT1 BCL2 BCL10
6 protein self-association GO:0043621 8.92 TP53 MYD88 MALT1 BCL10

Sources for Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....